Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

June 3, 2024

https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-publication-of-primary-cahtalyst-adult-phase-3-study-results-of-crinecerfont-for-the-treatment-of-cah-in-the-new-england-journal-of-medicine-302161424.html

     –          CAHtalyst™ Adult Phase 3 Study Met Primary and Important Key Secondary Endpoints, with Crinecerfont Treatment Decreasing Androstenedione Levels and Enabling Glucocorticoid Dose Reduction While Maintaining Androstenedione Control  
      –          62.7% of Crinecerfont Participants Achieved a Physiologic Glucocorticoid Dose while Maintaining Androstenedione Control versus 17.5% of Placebo Participants
     –          Favorable Trends in Endpoints Reflecting Consequences of Supraphysiologic Glucocorticoid Dosing
     –          Crinecerfont was Generally Well Tolerated

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.